NASDAQ OMX

DNAtix, the Genetics Blockchain Company, Introduces Complete Genome Sequencing Pilot and Announces Token Sale

Dela

Anonymous DNA Testing, Transfer, Storage with Total Control of Personal Data

 

AMSTERDAM, Netherlands, June 27, 2018 (GLOBE NEWSWIRE) -- Digital DNAtix Ltd., the genetics blockchain company, today announced the pilot of a breakthrough blockchain-based infrastructure and ecosystem for anonymous genetic testing, services and research. DNAtix is the first company to successfully transfer a genetic sequence over the Ethereum Blockchain. The DNAtix genetics ecosystem links individual users in the search of health solutions, or answers to ancestral questions, with products and services that fit their needs. DNAtix is also developing a dedicated Token - the DNATIX token - that will be integrated into the use of its DNAtix genetic platform.

"DNAtix is solving the privacy issue once and for all for testing highly sensitive DNA data with the first infrastructure blockchain ecosystem solution for anonymous genetic services," said Ofer A. Lidsky the CEO & CTO of the DNAtix. "Consumers, healthcare institutions, research centers, clinics, genetic counselors and others interested in using, testing, or gathering DNA data can now connect, work together for better health solutions and feel confident in sharing their genetic information."

Anyone can anonymously upload partial and/or full genome sequences onto the DNAtix platform; contributors own their genomic data and use it to make informed decisions.

Technology Breakthrough: An entire genetics ecosystem on the blockchain
Opening the door for advancements in research, new treatments, and cutting-edge personalized and preventive medicine, DNAtix's D2C platform provides full genome testing and access to services and solutions on the Blockchain and allows researchers to use anonymous DNA, stored on the DNAtix infrastructure, to create tests, do research and design new treatments.

In order to better leverage the emerging infrastructure and potential of blockchain genetic storage, DNAtix has developed and freely releases its compression algorithm for the mutual betterment of the field; Thus far, DNA storage efficiency has been increased by 300%.
GitHub repository: https://github.com/DNAtix/DNAtix-DNA-Compression-Tool

The DNATIX Token
DNAtix is in the private sale stage of its token to fund the delivery of anonymous genetic services at an affordable price point. The DNAtix token has smart contracts built into it enabling -for the first time- the anonymous and secure analysis, transfer, and storage of DNA sequences. The DNAtix wallet will facilitate anonymous payment for a wide range of genetic services. For more information and purchase instructions about DNAtix token sale, email:  info@dnatix.com.

SPEAKING: DNAtix AT BLOCKCHAIN EXPO EUROPE  
Ofer A. Lidsky will be presenting twice at Blockchain Expo Europe:

· Track:  Developing Blockchain Applications
· Day/Time:  Day 1 (27 June) 14:40 - 14:50
· Title: Introducing new developments 2 (When Blockchain Meets Genetics)
   
· Track: Blockchain Technologies
· Day/Time: Day 2 (28 June) 09:40 - 10:20
· Keynote Panel: What does the future hold for Blockchain technology - where do we think we will be in 2030?

More information: https://blockchain-expo.com/europe/speaker/senior-representative-dnatix/

ABOUT DNAtix
DNAtix, a cutting-edge genetics and blockchain company, is building the infrastructure for the world's genetic blockchain ecosystem where researchers, hospitals, developers, clinicians and others will develop next generation, decentralized genetics applications and health management solutions. DNAtix is also delivering a direct-to-consumer platform that offers anonymous and encrypted genome sequencing and genetic services, including digitized DNA analysis, storage and transfer.  The DNAtix genetics ecosystem is a place where consumers and the industry can meet to share genetic data in a more transparent, accessible, applicable and secured manner. DNAtix is developing the future ecosystem for Genetics which is Blockchain based and includes cutting edge new innovative ideas and technologies. With a first successful proof of concept already completed for transferring a DNA sequence over the Ethereum blockchain DNAtix is leading the world of Genetic blockchain.  www.dnatix.com 

Media Contact: 
Heidi Groshelle 
Groshelle Communications 
heidi@groshelle.com 
415.307.1380

A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f9e2aca-e48d-4d99-a20f-860e3995878b 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DNAtix via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum